Edesa Biotech, Inc. (EDSA) vs Nephros, Inc. (NEPH)
A side-by-side comparison of Edesa Biotech, Inc. and Nephros, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EDSA
Edesa Biotech, Inc.
$3.72HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NEPH
Nephros, Inc.
$3.02HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EDSA vs NEPH
growth of $100 · dividends reinvested · last 10yEDSA -99.4% (-40.3%/yr)NEPH +6.6% (+0.6%/yr)NEPH compounded faster over this window
Log scale — wide-divergence pair
EDSA NEPH
EDSA vs NEPH: by the numbers
- •EDSA is the larger company ($36M vs $33M market cap).
- •NEPH is profitable (8.38% net margin) while EDSA runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | EDSA | NEPH |
|---|---|---|
| P/E ratio | N/A | 19.03 |
| Forward P/E | N/A | 19.28 |
| P/S ratio | N/A | 1.58 |
| P/B ratio | 89.82 | 2.74 |
| EV / EBITDA | N/A | 16.41 |
Profitability
| Metric | EDSA | NEPH |
|---|---|---|
| Gross margin | 0.00% | 60.31% |
| Operating margin | 0.00% | 7.92% |
| Net margin | 0.00% | 8.38% |
| ROE | -160.05% | 14.51% |
| ROIC | -166.02% | 12.67% |
Growth (annualized)
| Metric | EDSA | NEPH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.99% |
| Total return CAGR (5Y) | -39.88% | -15.93% |
Frequently asked
- Is EDSA or NEPH more profitable?
- NEPH runs the higher net margin — EDSA at 0.00% versus NEPH at 8.38%.
- How have EDSA and NEPH total returns compared?
- Over the past 10 years, EDSA delivered -40.32% and NEPH delivered 1.80% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Nephros P/E ratioEdesa Biotech ROENephros ROEEdesa Biotech operating marginNephros operating marginEdesa Biotech revenue growthNephros revenue growthEdesa Biotech free cash flowNephros free cash flow
Edesa Biotech & Nephros appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.